lantus and glp 1 GLP-1 Agonists: Increasing Effective Insulin Release Insulin Glargine Plus Lixisenatide -

GH stimulation may theoretically encourage tumor growth, so this therapy is avoided in anyone with an active malignancy or a history of cancer that is not in complete remission

may be prescribed off-label for weight management at $90 per 3-month supply No lifestyle coaching, app-based tracking, or nutrition support is included

Ipamorelin is a ghrelin receptor agonist with minimal effect on cortisol or prolactin secretion, producing clean growth hormone pulses without the appetite stimulation (GHRP-6) or desensitization risk (Hexarelin) associated with other secretagogues

ADC species with no drug attached (DAR0 species) at best are subpotent and at worst can impact the overall potency of the ADC by taking away binding sites on tumor cells from more highly drugged species